P. Singh 1, A. Necchi 2, P. Giannatempo 2, G. Niegisch 3, G. di Lorenzo 4, C. Hsu 1, G. Sonpavde 5 University of Arizona Cancer Center 1, Tucson; Fondazione.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Advances and Emerging Therapy for Lung Cancer

Xeloda X-panding options in the adjuvant treatment of breast cancer

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD.

Facon T et al. Proc ASH 2013;Abstract 2.

CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.

Novel AKT Inhibitor Afuresertib in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.

LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Palumbo A et al. Proc ASH 2014;Abstract 175.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Taiwan 2000 Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized.

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Activation of insulin like growth factor 1 receptor (IGF-1R) signaling pathway is implicated in proliferation, survival, and angiogenesis in pancreatic.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

Tolerability of fluoropyrimidines differs by region Daniel G. Haller on behalf of: Cassidy J, Clarke S, Cunningham D, Van Cutsem E Hoff P, Rothenberg M,

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

Geisler C et al. Proc ASH 2011;Abstract 290.

CCO Independent Conference Coverage

Alessandra Gennari, MD PhD

IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma CCO Independent Conference Coverage* of the 2016.

Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.

KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer CCO Independent Conference Highlights* of.

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Vahdat L et al. Proc SABCS 2012;Abstract P

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Abraxane-Pembro nei carcinomi uroteliali avanzati

Case Discussion A 52-year-old man initially presented with nonmuscle-invasive bladder cancer He received Bacillus calmette-guerin (BCG) therapy After.

Intervista a Lucio Crinò

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Ospedale Misericordia, Grosseto

CTCL: INNOVATIVE TREATMENTS GEMCITABINE

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

Presentation transcript:

P. Singh 1, A. Necchi 2, P. Giannatempo 2, G. Niegisch 3, G. di Lorenzo 4, C. Hsu 1, G. Sonpavde 5 University of Arizona Cancer Center 1, Tucson; Fondazione IRCCS Istituto Nazionale dei Tumori 2,Milano,Italy; Heinrich-Heine- Universität 3, Düsseldorf; Università Federico II 4, Napoli, Italy; UAB cancer center 5, Birmigham. Conclusions: This retrospective clinical experience in UC with CrCl <60 ml/min and mostly ECOG-PS 0-1 suggests that cisplatin – based chemotherapy is feasible and warrants exploration given CRs induced in metastatic disease. Incorporation of prophylactic growth factors and modified schedules may mitigate myelosuppression. RESULTS REFERENCES Methods: Data were requested and retrospectively collected from 5 collaborating institutions. All patients had stage 2 or higher UC and CrCl < 60. Patient characteristics including age, sex, indication for chemotherapy (neoadjuvant, adjuvant or metastatic disease), schedule, total dose of cisplatin, adverse effects, renal function, blood cell counts and radiologic tumor response were collected. Descriptive statistics were employed with no baseline assumptions. Hussain, S.A., et al., A study of split-dose cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett, (4): p Galsky, M.D., et al., A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol, (3): p Sonpavde, G., et al., Cisplatin-Ineligible and Chemotherapy- Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer. Clin Genitourin Cancer, Hussain, S.A., et al., A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer, (5): p Results: Mean total dose of cisplatin used in all patients was ± mg, with 81.7% (n=85) patients receiving ≥70mg/m 2 dose per cycle. Percentage of patients with any toxicity with baseline CrCl 45 were 43.5% and 39.5%, respectively (p=0.81). Neutropenic infection occurred in 16.3% and thrombocytopenic bleed in 8.6%. Grade 3 renal toxicity was seen in only one patient (0.96%) and no toxic deaths were reported. Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction Background: Patients (pts) with UC and creatinine clearance (CrCl) < 60 ml/min are considered cisplatin-ineligible. Since the safety of cisplatin use in patients with CrCl < 60 has not been comprehensively studied, we conducted a retrospective study in this population VariableMean ± SDRange Total number of patients103 Age63.72±8.0641~77 Cr Cl (CG formula)50.78±7.9726~59 Dose ≥70 mg/m 2 85 (81.73%) ECOG Performance Status (PS) 074 (71.84%) 121 (20.39%) 28 (7.77)% ToxicityN (%) Any Toxicity42 (40.38%) CrClState<= 45 (N=23) 10 (43.48%) CrClState >45 (N=81) ToxicityN (%) Any Toxicity42 (40.38%) CrClState<=45 (N=23)10 (43.48%) CrClState >45 (N=81)32 (39.51%) p-value a 0.81 Neutropenicfever17 (16.35%) ECOG 0 (N=74)11 (14.86%) ECOG 1-2 (N=29)6 (20.69%) p-value0.56 CrClState<=45 (N=23)0 (0.0%) CrClState>45 (N=81)17 (20.99%) p-value0.02 Thrombocytopenic bleed9 (8.65%) CrClState<=45 (N=23)3 (13.04%) CrClState>45 (N=81)6 (7.41%) p-value0.41 Renal toxicity None95 (91.35%) Grade 16 (5.77%) Grade 22 (1.92%) Grade 31 (0.96%) Renal Toxicity (any grade) CrClState<=45 (N=23)1 (4.35%) CrClState>45 (N=81)8 (9.88%) p-value0.68 ECOG 0 (N=74)7 (9.46%) p-value a ECOG 1-2 (N=29)2 (6.9%) Neutropenic fever p-value1.00 ECOG 0 (N=74) Neuropathy ECOG 1-2 (N=29) None91 (87.50%) p-value Grade 110 (9.62%) CrClState<= 45 (N=23) Grade 23 (2.88%) CrClState>45 (N=81) Neuropathy (Grade 2) p-value CrClState<=45 (N=23)1 (4.35%) Thrombocyt openic bleed CrClState>45 (N=81)2 (2.47%) CrCl State<=45 (N=23) p-value0.53 CrCl State>45 (N=81) Best Responses (N=42 b ) p-value PR17 (40.48%) Renal toxicity CR3 (7.14%) None SD6 (14.29%) Grade 1 PD12 (28.57%) Grade 2 Not available4 (9.52%) Grade 3 Removed from study16 (15.38%) ToxicityN (%) Any Toxicity42 (40.38%) CrCl ≤45 (N=23)10 (43.48%) CrCl >45 (N=81)32 (39.51%) p-value a 0.81 Neutropenic fever17 (16.35%) ECOG 0 (N=74)11 (14.86%) ECOG 1-2 (N=29)6 (20.69%) p-value0.56 CrCl ≤ 45 (N=23)0 (0.0%) CrCl >45 (N=81)17 (20.99%) p-value0.02 Thrombocytopenic bleed 9 (8.65%) CrCl State<=45 (N=23)3 (13.04%) CrCl State>45 (N=81)6 (7.41%) p-value0.41 Renal toxicity None95 (91.35%) Grade 16 (5.77%) Grade 22 (1.92%) Grade 31 (0.96%) Renal Toxicity (any grade) CrCl ≤45 (N=23)1 (4.35%) CrCl >45 (N=81)8 (9.88%) p-value0.68 ECOG PS 0 (N=74)7 (9.46%) ECOG 1-2 (N=29)2 (6.9%) p-value1.00 Neuropathy None91 (87.50%) Grade 110 (9.62%) Grade 23 (2.88%) Neuropathy (Grade 2) CrCl ≤45 (N=23)1 (4.35%) CrCl >45 (N=81)2 (2.47%) p-value0.53 Best Responses (N=42) PR17 (40.48%) CR3 (7.14%) SD6 (14.29%) PD12 (28.57%) Not available4 (9.52%) Removed from study16 (15.38%)